Skip to main content
Clinical Trials/JPRN-jRCT2080220660
JPRN-jRCT2080220660UnknownPhase 3

Randomized trial of oxaliplatin plus S-1 (SOX) versus S-1 alone in patients with gemcitabine-refractory pancreatic cancer

Yakult Honsha Co.,Ltd.0 sites240 target enrollmentStarted: January 23, 2009Last updated:

Trial Snapshot

Phase
Phase 3
Enrollment
240

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
>= 20age old to ot applicable (—)
Sex
All

Inclusion Criteria

  • Histologically or cytologically proven pancreatic adenocarcinoma or adenosquamous carcinoma
  • Gemcitabine refractory
  • Taking orally
  • ECOG performance status (PS) :0-1
  • Measurable metastatic disease based on RECIST criteria

Exclusion Criteria

  • Prior treatment with platinum- or fluoropyrimidine -agent
  • Prior treatment with radiotherapy

Investigators

Similar Trials

Randomized trial of oxaliplatin plus S-1... | Clinical Trial